Ciliatech’s groundbreaking CID (Cilio-Scleral Inter-positioning Device) technology proves that a significant IOP decrease can be achieved while leaving the anterior chamber untouched and without altering the eye’s anterior segment.
All other glaucoma implants, whatever the chosen outflow route (subconjunctival filtration, trabecular stent, cyclodialysis), penetrate the anterior chamber and remain partly in it. It is known by literature that any device close to the corneal endothelium is potentially harmful to corneal endothelial cells.
In contrast, a CID surgical procedure distances itself from the anterior chamber, making it a very safe and significantly different method to all intracameral implants. As there is no risk of a CID implant being in contact with, or close to, the cornea; there is, therefore, no ECL (corneal Endothelial Cell Loss) risk ‘by design’.
As a CID implant is neither in contact with, nor close to, the cornea, a CID surgery:
Ciliatech’s CID implant is a non-resorbable implant which remains in place for the patient’s lifetime.
It is a one-piece of 26% hydrophilic acrylic, a raw material widely used in the manufacturing of intra-ocular lenses, which ensures long-term biocompatibility.
It consists of a specifically designed 6mm large, 4 mm wide, and 200µm thick plate*. The device’s two faces and edges are designed with grooves and corrugations to maximise the outflow from the anterior chamber and its circulation to the choroid and the sclera-conjunctival vessels
**Based on internal data: interim results at 12M / 6M follow-up SAFARI 1 / SAFARI 2 studies resp.